false000183233200018323322023-11-092023-11-09
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 9, 2023
Aveanna Healthcare Holdings Inc.
(Exact name of Registrant as Specified in Its Charter)
|
|
|
Delaware |
001-40362 |
81-4717209 |
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
400 Interstate North Parkway SE, Atlanta, GA 30339 (Address of Principal Executive Offices, including Zip Code) |
(770)-441-1580
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
Common Stock, par value $0.01 per share |
|
AVAH |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 9, 2023, Aveanna Healthcare Holdings Inc. (“we,” “us,” “our” or the “Company”) issued a press release announcing its financial results for the three and nine-month periods ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference in this Item 2.02.
Item 7.01 Regulation FD Disclosure.
The information contained in Item 2.02 of this Current Report on Form 8-K is incorporated by reference in this Item 7.01.
The information contained in this Current Report on Form 8-K, including in Exhibit 99.1 attached hereto, is “furnished” and not “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. Such information shall not be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, except to the extent such other filing specifically incorporates such information by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
AVEANNA HEALTHCARE HOLDINGS INC. |
|
|
|
|
Date: November 9, 2023 |
|
By: |
/s/ Deborah Stewart |
|
|
|
Deborah Stewart |
|
|
|
Chief Accounting Officer (Principal Accounting Officer) |
Exhibit 99.1
AVEANNA HEALTHCARE HOLDINGS ANNOUNCES
THIRD QUARTER 2023 FINANCIAL RESULTS
•Revenue was $478.0 million, a 7.9% increase over the prior year
oGross margin increased 9.4% to $147.3 million, compared to Q3 2022
•Net loss was $102.4 million, inclusive of a $105.1 million non-cash goodwill impairment, compared to net income of $24.3 million in the comparable prior year period
oAdjusted EBITDA was $36.2 million, a 46.2% increase as compared to the prior year
•Full year 2023 revenue guidance raised to a range of $1,870 million to $1,880 million
oFull year 2023 Adjusted EBITDA guidance raised to a range of $134 million to $137 million
Atlanta, Georgia (November 9, 2023) – Aveanna Healthcare Holdings Inc. (NASDAQ: AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced financial results for the three and nine-month periods ended September 30, 2023.
Jeff Shaner, Chief Executive Officer, commented “Our third quarter results reflect the continued momentum in our business, highlighted by revenue and Adjusted EBITDA growth of 7.9% and 46.2% when compared to the prior year period. These strong results further affirm the Aveanna strategy to adapt and transform our business as we execute on our 2023 key initiatives. Enhanced payor partnerships allow us to further invest in our caregivers and broaden our care to more patients in need. We are delivering high-quality care to our patients at an exceptional value to our government and payor partners. I am proud of our Aveanna teammates' efforts and the solid results they produced for the third quarter. We are confident in our revised outlook for the remainder of 2023.”
Three-Month Periods Ended September 30, 2023 and October 1, 2022
Revenue was $478.0 million for the three-month period ended September 30, 2023, as compared to $443.0 million for the three-month period ended October 1, 2022, an increase of $35.0 million, or 7.9%. The overall increase in revenue was attributable to a $29.1 million increase in Private Duty Services (“PDS”) segment revenue, a $2.7 million increase in Medical Solutions ("MS") segment revenue, and a $3.1 million increase in Home Health & Hospice (“HHH”) segment revenue over the comparable quarter.
Gross margin was $147.3 million, or 30.8% of revenue, for the three months ended September 30, 2023, as compared to $134.6 million, or 30.4% of revenue, for the three months ended October 1, 2022, an increase of $12.7 million, or 9.4%.
Net loss was $102.4 million for the third quarter of 2023, as compared to net income of $24.3 million for the third quarter of 2022, primarily attributable to a $105.1 million non-cash goodwill impairment charge recorded in the third quarter of 2023. Net loss per diluted share was $(0.54) for the third quarter of 2023, as compared to net income per diluted share of $0.13 for the third quarter of 2022. Adjusted net loss per diluted share was $(0.03) for the third quarter of 2023, as compared to adjusted net loss per diluted share of $(0.03) for the third quarter of 2022.
Adjusted EBITDA was $36.2 million, or 7.6% of revenue, for the third quarter of 2023, as compared to $24.7 million, or 5.6% of revenue, for the third quarter of 2022. See "Non-GAAP Financial Measures - EBITDA and Adjusted EBITDA" below.
Nine-Month Periods Ended September 30, 2023 and October 1, 2022
1
Revenue was $1,416.4 million for the nine-month period ended September 30, 2023, as compared to $1,336.5 million for the nine-month period ended October 1, 2022, an increase of $79.9 million, or 6.0%. The overall increase in revenue was attributable to a $81.5 million increase in the PDS segment revenue and a $11.7 million increase in the MS segment revenue, partially offset by a $13.3 million decrease in the HHH segment revenue over the comparable period.
Gross margin was $447.0 million, or 31.6% of revenue, for the nine-month period ended September 30, 2023, as compared to $424.5 million, or 31.8% of revenue, for the nine-month period ended October 1, 2022, an increase of $22.5 million, or 5.3%.
Net loss was $108.8 million for the first nine months of 2023, as compared to net loss of $424.3 million for the first nine months of 2022, primarily attributable to the difference in non-cash goodwill impairment charges recorded in the respective periods. Net loss per diluted share was $(0.57) for the first nine months of 2023, as compared to net loss per diluted share of $(2.29) for the first nine months of 2022. Adjusted net loss per diluted share was $(0.09) for the first nine months of 2023, as compared to adjusted net income per diluted share of $0.04 for the first nine months of 2022.
Adjusted EBITDA was $100.5 million, or 7.1% of revenue, for the first nine months of 2023, as compared to $99.7 million, or 7.5% of revenue, for the first nine months of 2022.
Liquidity, Cash Flow, and Debt
•As of September 30, 2023, we had cash of $48.3 million and incremental borrowing capacity of $20.0 million under our securitization facility. Our revolver was undrawn, with approximately $168.0 million of borrowing capacity and approximately $32.0 million of outstanding letters of credit.
•Fiscal year-to-date 2023 net cash provided by operating activities was $25.7 million. Free cash flow was $16.9 million for year-to-date 2023. See “Non-GAAP Financial Measures - Free cash flow” below.
•As of September 30, 2023 we had bank debt of $1,472.1 million. Our interest rate exposure under our credit facilities is currently hedged with the following instruments:
o$520.0 million notional amount of interest rate swaps that convert variable rate debt to a fixed rate, and
o$880.0 million notional amount of interest rate caps that cap our exposure to SOFR at 2.96%.
The leverage maintenance covenants in our revolving credit facility do not become operative unless more than 30% of the total commitment under the revolving credit facility has been utilized, subject to a $15.0 million carve-out for letters of credit. Should the leverage maintenance covenant become operative, maximum allowable first lien leverage would be 7.6x.
Matt Buckhalter, Interim Chief Financial Officer, commented “I am pleased with the continued execution of our 2023 strategic initiatives during the third quarter. Aveanna’s performance is highlighted by the 7.9% growth in revenue and 46.2% growth in Adjusted EBITDA as compared to prior year period. The cost reduction efforts implemented earlier this year have positively impacted our cash flow generated from operations in Q3. Additionally, the demonstrated success of our preferred payor and government partner strategy gives us confidence in our revised 2023 guidance.”
Revised Full Year 2023 Guidance
The following is our updated guidance reflecting our current expectations for revenue and Adjusted EBITDA for the full year 2023:
•Revenue of between $1,870 million and $1,880 million, updated from prior guidance of revenue of between $1,850 million and $1,860 million
Consistent with prior practice, we are not providing guidance on net income at this time due to the volatility of certain required inputs that are not available without unreasonable efforts, including future fair value adjustments associated with our interest rate swaps and caps.
•Adjusted EBITDA of between $134 million and $137 million, updated from prior guidance of Adjusted EBITDA between $132 million and $135 million
2
Non-GAAP Financial Measures
In addition to our results of operations prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), we also evaluate our financial performance using EBITDA, Adjusted EBITDA, Field contribution, Field contribution margin, Adjusted net income, Adjusted net income per diluted share, and Free cash flow. Given our determination of adjustments in arriving at our computations, these non-GAAP measures have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to net income or loss, revenue, operating income or loss, cash flows from operating activities, total indebtedness or any other financial measures calculated in accordance with GAAP. The reconciliations of these non-GAAP financial measures to their most directly comparable GAAP measures are included in the financial tables below.
EBITDA and Adjusted EBITDA
EBITDA and Adjusted EBITDA are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with GAAP, such as net income (loss). Rather, we present EBITDA and Adjusted EBITDA as supplemental measures of our performance. We define EBITDA as net income (loss) before interest expense, net; income tax benefit (expense); and depreciation and amortization. We define Adjusted EBITDA as EBITDA, adjusted for the impact of certain other items that are either non-recurring, infrequent, non-cash, unusual, or items deemed by management to not be indicative of the performance of our core operations, including impairments of goodwill, intangible assets, and other long-lived assets; non-cash, share-based compensation; loss on extinguishment of debt; fees related to debt modifications; the effect of interest rate derivatives; acquisition-related and integration costs; legal costs and settlements associated with acquisition matters; COVID-19 related costs; restructuring costs; other legal matters; and other system transition costs, professional fees and other costs. As non-GAAP financial measures, our computations of EBITDA and Adjusted EBITDA may vary from similarly termed non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of this measure impracticable.
We believe our computations of EBITDA and Adjusted EBITDA are helpful in highlighting trends in our core operating performance. In determining which adjustments are made to arrive at EBITDA and Adjusted EBITDA, we consider both (1) certain non-recurring, infrequent, non-cash or unusual items, which can vary significantly from year to year, as well as (2) certain other items that may be recurring, frequent, or settled in cash but which we do not believe are indicative of our core operating performance. We use EBITDA and Adjusted EBITDA to assess operating performance and make business decisions.
We have incurred substantial acquisition-related costs and integration costs. The underlying acquisition activities take place over a defined timeframe, have distinct project timelines and are incremental to activities and costs that arise in the ordinary course of our business. Therefore, we believe it is important to exclude these costs from our Adjusted EBITDA because it provides us a normalized view of our core, ongoing operations after integrating our acquired companies, which we believe is an important measure in assessing our performance.
Field contribution and Field contribution margin
Field contribution and Field contribution margin are non-GAAP financial measures and are not intended to replace financial performance measures determined in accordance with GAAP, such as gross margin and gross margin percentage. Rather, we present Field contribution and Field contribution margin as supplemental measures of our performance. We define Field contribution as gross margin less branch and regional administrative expenses. Field contribution margin is Field contribution as a percentage of revenue. As non-GAAP financial measures, our computations of Field contribution and Field contribution margin may vary from similarly termed non-GAAP financial measures used by other companies, making comparisons with other companies on the basis of these measures impracticable.
Field contribution and Field contribution margin have limitations as analytical tools and should not be considered in isolation or as substitutes or alternatives to gross margin, gross margin percentage, net income or loss, revenue, operating income or loss, cash flows from operating activities, total indebtedness or any other financial measures calculated in accordance with GAAP.
Management believes Field contribution and Field contribution margin are helpful in highlighting trends in our core operating performance and evaluating trends in our branch and regional results, which can vary from year to year. We use Field contribution and Field contribution margin to make business decisions and assess the operating performance and results delivered by our core field operations, prior to corporate and other costs not directly related to our field operations. These metrics are also important because they guide us in determining whether or not our branch and regional administrative expenses are appropriately sized to support our caregivers
3
and direct patient care operations. Additionally, Field contribution and Field contribution margin determine how effective we are in managing our field supervisory and administrative costs associated with supporting our provision of services and sale of products.
Adjusted net (loss) income and Adjusted net (loss) income per diluted share
Adjusted net (loss) income represents net income (loss) as adjusted for the impact of GAAP income tax, goodwill, intangible and other long-lived asset impairment charges, non-cash share-based compensation expense, loss on extinguishment of debt, interest rate derivatives, acquisition-related costs, integration costs, legal costs, COVID-related costs net of reimbursement, restructuring costs, other legal matters, other system transition costs, professional fees and certain other miscellaneous items on a pre-tax basis. Adjusted net (loss) income includes a provision for income taxes derived utilizing a combined statutory tax rate. The combined statutory tax rate is our estimate of our long-term tax rate. The most comparable GAAP measure is net income (loss).
Adjusted net (loss) income per diluted share represents adjusted net (loss) income on a per diluted share basis using the weighted-average number of diluted shares outstanding for the period. The most comparable GAAP measure is net income (loss) per share, diluted.
Adjusted net (loss) income and adjusted net (loss) income per diluted share are important to us because they allow us to assess financial results, exclusive of the items mentioned above that are not operational in nature or comparable to those of our competitors.
Free cash flow
Free cash flow is a liquidity measure that represents operating cash flow, adjusted for the impact of purchases of property, equipment and software, principal payments on term loans, notes payable and financing leases, and settlements with swap counterparties. The most comparable GAAP measure is cash flow from operations.
We believe free cash flow is helpful in highlighting the cash generated or used by the Company, after taking into consideration mandatory payments on term loans, notes payable and financing leases, as well as cash needed for non-acquisition related capital expenditures, and cash paid to or received from derivative counterparties.
Conference Call
Aveanna will host a conference call on Thursday, November 9, 2023, at 10:00 a.m. Eastern Time to discuss our third quarter 2023 results. The conference call can be accessed live over the phone by dialing 1-877-407-0789, or for international callers, 1-201-689-8562. A telephonic replay of the conference call will be available until November 16, 2023, by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the replay is 13740762. A live webcast of our conference call will also be available under the Investor Relations section of our website: https://ir.aveanna.com/. The online replay will also be available for one week following the call.
Forward-Looking Statements
Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this press release regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward-looking statements. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “would,” “predict,” “project,” “potential,” “continue,” “could,” “design,” or the negatives of these terms or variations of them or similar expressions. These statements are based on certain assumptions that we have made in light of our experience in the industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. Forward-looking statements involve a number of risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward-looking statements, such as our ability to successfully execute our growth strategy, including through organic growth and the completion of acquisitions, effective integration of the companies we acquire, unexpected costs of acquisitions and dispositions, the possibility that expected cost synergies may not materialize as expected, the failure of Aveanna or the companies we acquire to perform as expected, estimation inaccuracies in revenue recognition, our ability to drive margin leverage through lower costs, unexpected increases in SG&A and other expenses, changes in reimbursement, changes in government regulations, changes in Aveanna’s relationships with referral sources, increased competition for Aveanna’s services or wage inflation, the failure to retain or attract employees, changes in the interpretation of government regulations or discretionary determinations made by government officials, uncertainties regarding the outcome of rate discussions with managed care organizations and our ability to effectively collect our cash from these organizations, changes in the case-mix of our patients, as well as the payor mix and payment methodologies, legal proceedings, claims or governmental inquiries, our ability to effectively collect and submit data required under Electronic Visit Verification regulations, our ability to comply with the terms and conditions of the CMS Review Choice Demonstration program, our ability to effectively implement and transition
4
to new electronic medical record systems or billing and collection systems, a failure to maintain the security and functionality of our information systems or to defend against or otherwise prevent a cybersecurity attack or breach, changes in tax rates, our substantial indebtedness, the impact of adverse weather, the impact to our business operations, reimbursements and patient population were the COVID-19 environment to worsen, and other risks set forth under the heading “Risk Factors” in Aveanna’s Annual Report on Form 10-K for its 2022 fiscal year filed with the Securities and Exchange Commission on March 16, 2023, which is available at www.sec.gov. In addition, these forward-looking statements necessarily depend upon assumptions, estimates and dates that may prove to be incorrect or imprecise. Accordingly, forward-looking statements included in this press release do not purport to be predictions of future events or circumstances, and actual results may differ materially from those expressed by forward-looking statements. All forward-looking statements speak only as of the date made, and Aveanna undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
About Aveanna Healthcare
Aveanna Healthcare is headquartered in Atlanta, Georgia and has locations in 33 states providing a broad range of pediatric and adult healthcare services including nursing, rehabilitation services, occupational nursing in schools, therapy services, day treatment centers for medically fragile and chronically ill children and adults, home health and hospice services, as well as delivery of enteral nutrition and other products to patients. The Company also provides case management services in order to assist families and patients by coordinating the provision of services between insurers or other payers, physicians, hospitals, and other healthcare providers. In addition, the Company provides respite healthcare services, which are temporary care provider services provided in relief of the patient’s normal caregiver. The Company’s services are designed to provide a high quality, lower cost alternative to prolonged hospitalization. For more information, please visit www.aveanna.com.
5
Cash Flow and Information about Indebtedness
The following table sets forth a summary of our cash flows from operating, investing, and financing activities for the periods presented:
|
|
|
|
|
|
|
|
|
For the nine-month periods ended |
|
(dollars in thousands) |
September 30, 2023 |
|
|
October 1, 2022 |
|
Net cash provided by (used in) operating activities |
$ |
25,677 |
|
|
$ |
(8,166 |
) |
Net cash used in investing activities |
$ |
(7,226 |
) |
|
$ |
(22,092 |
) |
Net cash provided by financing activities |
$ |
10,626 |
|
|
$ |
63,449 |
|
Cash and cash equivalents at beginning of period |
$ |
19,217 |
|
|
$ |
30,490 |
|
Cash and cash equivalents at end of period |
$ |
48,294 |
|
|
$ |
63,681 |
|
The following table presents our long-term indebtedness as of September 30, 2023:
|
|
|
|
|
|
(dollars in thousands) |
|
|
|
|
Instrument |
Interest Rate |
|
September 30, 2023 |
|
2021 Extended Term Loan (1) |
S + 3.75% |
|
$ |
902,050 |
|
Second Lien Term Loan (1) |
S + 7.00% |
|
|
415,000 |
|
Revolving Credit Facility (2) |
S + 3.75% |
|
|
- |
|
Securitization Facility |
S + 3.50% |
|
|
155,000 |
|
Total indebtedness |
|
|
$ |
1,472,050 |
|
(1) S = Greater of 0.50% or one-month SOFR, plus a CSA |
|
|
|
|
(2) S = One-month SOFR, plus a CSA |
|
|
|
|
Results of Operations
The following table summarizes our consolidated results of operations for the periods indicated (amounts in thousands, except per share data):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three-month periods ended |
|
For the nine-month periods ended |
|
|
September 30, 2023 |
|
October 1, 2022 |
|
September 30, 2023 |
|
October 1, 2022 |
|
Revenue |
$ |
478,010 |
|
$ |
443,009 |
|
$ |
1,416,368 |
|
$ |
1,336,498 |
|
Cost of revenue, excluding depreciation and amortization |
|
330,746 |
|
|
308,426 |
|
|
969,384 |
|
|
912,046 |
|
Branch and regional administrative expenses |
|
91,004 |
|
|
89,542 |
|
|
273,967 |
|
|
267,283 |
|
Corporate expenses |
|
27,446 |
|
|
33,215 |
|
|
84,735 |
|
|
105,984 |
|
Goodwill impairment |
|
105,136 |
|
|
- |
|
|
105,136 |
|
|
470,207 |
|
Depreciation and amortization |
|
2,962 |
|
|
4,917 |
|
|
10,494 |
|
|
16,774 |
|
Acquisition-related costs |
|
428 |
|
|
- |
|
|
466 |
|
|
69 |
|
Other operating (income) expense |
|
(3,360 |
) |
|
2,122 |
|
|
(6,593 |
) |
|
1,953 |
|
Operating (loss) income |
|
(76,352 |
) |
|
4,787 |
|
|
(21,221 |
) |
|
(437,818 |
) |
Interest income |
|
50 |
|
|
164 |
|
|
238 |
|
|
369 |
|
Interest expense |
|
(39,599 |
) |
|
(28,462 |
) |
|
(113,542 |
) |
|
(73,745 |
) |
Other income |
|
14,143 |
|
|
45,140 |
|
|
27,124 |
|
|
86,523 |
|
(Loss) income before income taxes |
|
(101,758 |
) |
|
21,629 |
|
|
(107,401 |
) |
|
(424,671 |
) |
Income tax (expense) benefit |
|
(631 |
) |
|
2,669 |
|
|
(1,387 |
) |
|
416 |
|
Net (loss) income |
$ |
(102,389 |
) |
$ |
24,298 |
|
$ |
(108,788 |
) |
$ |
(424,255 |
) |
Net (loss) income per share: |
|
|
|
|
|
|
|
|
Net (loss) income per share, basic |
$ |
(0.54 |
) |
$ |
0.13 |
|
$ |
(0.57 |
) |
$ |
(2.29 |
) |
Weighted average shares of common stock outstanding, basic |
|
189,139 |
|
|
186,113 |
|
|
189,632 |
|
|
185,327 |
|
Net (loss) income per share, diluted |
$ |
(0.54 |
) |
$ |
0.13 |
|
$ |
(0.57 |
) |
$ |
(2.29 |
) |
Weighted average shares of common stock outstanding, diluted |
|
189,139 |
|
|
186,166 |
|
|
189,632 |
|
|
185,327 |
|
6
The following tables summarize our consolidated key performance measures, including Field contribution and Field contribution margin, which are non-GAAP measures, for the periods indicated:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three-month periods ended |
|
(dollars in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
Change |
|
% Change |
|
Revenue |
$ |
478,010 |
|
$ |
443,009 |
|
$ |
35,001 |
|
|
7.9 |
% |
Cost of revenue, excluding depreciation and amortization |
|
330,746 |
|
|
308,426 |
|
|
22,320 |
|
|
7.2 |
% |
Gross margin |
$ |
147,264 |
|
$ |
134,583 |
|
$ |
12,681 |
|
|
9.4 |
% |
Gross margin percentage |
|
30.8 |
% |
|
30.4 |
% |
|
|
|
|
Branch and regional administrative expenses |
|
91,004 |
|
|
89,542 |
|
|
1,462 |
|
|
1.6 |
% |
Field contribution |
$ |
56,260 |
|
$ |
45,041 |
|
$ |
11,219 |
|
|
24.9 |
% |
Field contribution margin |
|
11.8 |
% |
|
10.2 |
% |
|
|
|
|
Corporate expenses |
$ |
27,446 |
|
$ |
33,215 |
|
$ |
(5,769 |
) |
|
-17.4 |
% |
As a percentage of revenue |
|
5.7 |
% |
|
7.5 |
% |
|
|
|
|
Operating (loss) income |
$ |
(76,352 |
) |
$ |
4,787 |
|
$ |
(81,139 |
) |
|
1695.0 |
% |
As a percentage of revenue |
|
-16.0 |
% |
|
1.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the nine-month periods ended |
|
(dollars in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
Change |
|
% Change |
|
Revenue |
$ |
1,416,368 |
|
$ |
1,336,498 |
|
$ |
79,870 |
|
|
6.0 |
% |
Cost of revenue, excluding depreciation and amortization |
|
969,384 |
|
|
912,046 |
|
|
57,338 |
|
|
6.3 |
% |
Gross margin |
$ |
446,984 |
|
$ |
424,452 |
|
$ |
22,532 |
|
|
5.3 |
% |
Gross margin percentage |
|
31.6 |
% |
|
31.8 |
% |
|
|
|
|
Branch and regional administrative expenses |
|
273,967 |
|
|
267,283 |
|
|
6,684 |
|
|
2.5 |
% |
Field contribution |
$ |
173,017 |
|
$ |
157,169 |
|
$ |
15,848 |
|
|
10.1 |
% |
Field contribution margin |
|
12.2 |
% |
|
11.8 |
% |
|
|
|
|
Corporate expenses |
$ |
84,735 |
|
$ |
105,984 |
|
$ |
(21,249 |
) |
|
-20.0 |
% |
As a percentage of revenue |
|
6.0 |
% |
|
7.9 |
% |
|
|
|
|
Operating loss |
$ |
(21,221 |
) |
$ |
(437,818 |
) |
$ |
416,597 |
|
|
95.2 |
% |
As a percentage of revenue |
|
-1.5 |
% |
|
-32.8 |
% |
|
|
|
|
The following tables summarize our key performance measures by segment for the periods indicated:
7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDS |
|
|
|
For the three-month periods ended |
|
|
(dollars and hours in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
Change |
|
% Change |
|
|
Revenue |
$ |
384,750 |
|
$ |
355,620 |
|
$ |
29,130 |
|
|
8.2 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
280,288 |
|
|
254,756 |
|
|
25,532 |
|
|
10.0 |
% |
|
Gross margin |
$ |
104,462 |
|
$ |
100,864 |
|
$ |
3,598 |
|
|
3.6 |
% |
|
Gross margin percentage |
|
27.2 |
% |
|
28.4 |
% |
|
|
|
-1.2 |
% |
(4) |
Hours |
|
10,090 |
|
|
9,652 |
|
|
438 |
|
|
4.5 |
% |
|
Revenue rate |
$ |
38.13 |
|
$ |
36.84 |
|
$ |
1.29 |
|
|
3.7 |
% |
(1) |
Cost of revenue rate |
$ |
27.78 |
|
$ |
26.39 |
|
$ |
1.39 |
|
|
5.5 |
% |
(2) |
Spread rate |
$ |
10.35 |
|
$ |
10.45 |
|
$ |
(0.10 |
) |
|
-0.9 |
% |
(3) |
|
|
|
|
|
|
|
|
|
|
|
HHH |
|
|
|
For the three-month periods ended |
|
|
(dollars and admissions/episodes in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
Change |
|
% Change |
|
|
Revenue |
$ |
52,989 |
|
$ |
49,853 |
|
$ |
3,136 |
|
|
6.3 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
27,597 |
|
|
32,968 |
|
|
(5,371 |
) |
|
-16.3 |
% |
|
Gross margin |
$ |
25,392 |
|
$ |
16,885 |
|
$ |
8,507 |
|
|
50.4 |
% |
|
Gross margin percentage |
|
47.9 |
% |
|
33.9 |
% |
|
|
|
14.0 |
% |
(4) |
Home health total admissions (5) |
|
9.3 |
|
|
11.3 |
|
|
(2.0 |
) |
|
-17.7 |
% |
|
Home health episodic admissions (6) |
|
7.0 |
|
|
7.0 |
|
|
- |
|
|
0.0 |
% |
|
Home health total episodes (7) |
|
11.2 |
|
|
11.4 |
|
|
(0.2 |
) |
|
-1.8 |
% |
|
Home health revenue per completed episode (8) |
$ |
3,046 |
|
$ |
3,023 |
|
$ |
23 |
|
|
0.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
MS |
|
|
|
For the three-month periods ended |
|
|
(dollars and UPS in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
Change |
|
% Change |
|
|
Revenue |
$ |
40,271 |
|
$ |
37,536 |
|
$ |
2,735 |
|
|
7.3 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
22,861 |
|
|
20,702 |
|
|
2,159 |
|
|
10.4 |
% |
|
Gross margin |
$ |
17,410 |
|
$ |
16,834 |
|
$ |
576 |
|
|
3.4 |
% |
|
Gross margin percentage |
|
43.2 |
% |
|
44.8 |
% |
|
|
|
-1.6 |
% |
(4) |
Unique patients served (“UPS”) |
|
88 |
|
|
81 |
|
|
7 |
|
|
8.6 |
% |
|
Revenue rate |
$ |
457.63 |
|
$ |
463.41 |
|
$ |
(5.78 |
) |
|
-1.3 |
% |
(1) |
Cost of revenue rate |
$ |
259.78 |
|
$ |
255.58 |
|
$ |
4.20 |
|
|
1.8 |
% |
(2) |
Spread rate |
$ |
197.84 |
|
$ |
207.83 |
|
$ |
(9.98 |
) |
|
-5.2 |
% |
(3) |
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PDS |
|
|
|
For the nine-month periods ended |
|
|
(dollars and hours in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
Change |
|
% Change |
|
|
Revenue |
$ |
1,135,365 |
|
$ |
1,053,835 |
|
$ |
81,530 |
|
|
7.7 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
815,221 |
|
|
753,266 |
|
|
61,955 |
|
|
8.2 |
% |
|
Gross margin |
$ |
320,144 |
|
$ |
300,569 |
|
$ |
19,575 |
|
|
6.5 |
% |
|
Gross margin percentage |
|
28.2 |
% |
|
28.5 |
% |
|
|
|
-0.3 |
% |
(4) |
Hours |
|
29,738 |
|
|
28,868 |
|
|
870 |
|
|
3.0 |
% |
|
Revenue rate |
$ |
38.18 |
|
$ |
36.51 |
|
$ |
1.67 |
|
|
4.7 |
% |
(1) |
Cost of revenue rate |
$ |
27.41 |
|
$ |
26.09 |
|
$ |
1.32 |
|
|
5.2 |
% |
(2) |
Spread rate |
$ |
10.77 |
|
$ |
10.41 |
|
$ |
0.36 |
|
|
3.5 |
% |
(3) |
|
|
|
|
|
|
|
|
|
|
|
HHH |
|
|
|
For the nine-month periods ended |
|
|
(dollars and admissions/episodes in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
Change |
|
% Change |
|
|
Revenue |
$ |
164,525 |
|
$ |
177,858 |
|
$ |
(13,333 |
) |
|
-7.5 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
87,189 |
|
|
98,933 |
|
|
(11,744 |
) |
|
-11.9 |
% |
|
Gross margin |
$ |
77,336 |
|
$ |
78,925 |
|
$ |
(1,589 |
) |
|
-2.0 |
% |
|
Gross margin percentage |
|
47.0 |
% |
|
44.4 |
% |
|
|
|
2.6 |
% |
(4) |
Home health total admissions (5) |
|
30.9 |
|
|
38.0 |
|
|
(7.1 |
) |
|
-18.7 |
% |
|
Home health episodic admissions (6) |
|
21.8 |
|
|
23.3 |
|
|
(1.5 |
) |
|
-6.4 |
% |
|
Home health total episodes (7) |
|
34.2 |
|
|
37.5 |
|
|
(3.3 |
) |
|
-8.8 |
% |
|
Home health revenue per completed episode (8) |
$ |
3,022 |
|
$ |
2,978 |
|
$ |
44 |
|
|
1.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
MS |
|
|
|
For the nine-month periods ended |
|
|
(dollars and UPS in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
Change |
|
% Change |
|
|
Revenue |
$ |
116,478 |
|
$ |
104,805 |
|
$ |
11,673 |
|
|
11.1 |
% |
|
Cost of revenue, excluding depreciation and amortization |
|
66,974 |
|
|
59,847 |
|
|
7,127 |
|
|
11.9 |
% |
|
Gross margin |
$ |
49,504 |
|
$ |
44,958 |
|
$ |
4,546 |
|
|
10.1 |
% |
|
Gross margin percentage |
|
42.5 |
% |
|
42.9 |
% |
|
|
|
-0.4 |
% |
(4) |
Unique patients served (“UPS”) |
|
258 |
|
|
237 |
|
|
21 |
|
|
8.9 |
% |
|
Revenue rate |
$ |
451.47 |
|
$ |
442.22 |
|
$ |
9.25 |
|
|
2.2 |
% |
(1) |
Cost of revenue rate |
$ |
259.59 |
|
$ |
252.52 |
|
$ |
7.07 |
|
|
3.0 |
% |
(2) |
Spread rate |
$ |
191.88 |
|
$ |
189.70 |
|
$ |
2.18 |
|
|
1.2 |
% |
(3) |
1)Represents the period over period change in revenue rate, plus the change in revenue rate attributable to the change in volume.
2)Represents the period over period change in cost of revenue rate, plus the change in cost of revenue rate attributable to the change in volume.
3)Represents the period over period change in spread rate, plus the change in spread rate attributable to the change in volume.
4)Represents the change in margin percentage year over year (or quarter over quarter).
5)Represents home health episodic and fee-for-service admissions.
6)Represents home health episodic admissions.
7)Represents episodic admissions and recertifications.
8)Represents Medicare revenue per completed episode.
The following table reconciles gross margin and gross margin percentage to Field contribution and Field contribution margin:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three-month periods ended |
|
For the nine-month periods ended |
|
(dollars in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
September 30, 2023 |
|
October 1, 2022 |
|
Gross margin |
$ |
147,264 |
|
$ |
134,583 |
|
$ |
446,984 |
|
$ |
424,452 |
|
Branch and regional administrative expenses |
|
91,004 |
|
|
89,542 |
|
|
273,967 |
|
|
267,283 |
|
Field contribution |
$ |
56,260 |
|
$ |
45,041 |
|
$ |
173,017 |
|
$ |
157,169 |
|
Revenue |
$ |
478,010 |
|
$ |
443,009 |
|
$ |
1,416,368 |
|
$ |
1,336,498 |
|
Field contribution margin |
|
11.8 |
% |
|
10.2 |
% |
|
12.2 |
% |
|
11.8 |
% |
9
The following table reconciles net income (loss) to EBITDA and Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three-month periods ended |
|
For the nine-month periods ended |
|
(dollars in thousands) |
|
September 30, 2023 |
|
October 1, 2022 |
|
September 30, 2023 |
|
October 1, 2022 |
|
Net (loss) income |
|
$ |
(102,389 |
) |
$ |
24,298 |
|
$ |
(108,788 |
) |
$ |
(424,255 |
) |
Interest expense, net |
|
|
39,549 |
|
|
28,298 |
|
|
113,304 |
|
|
73,376 |
|
Income tax expense (benefit) |
|
|
631 |
|
|
(2,669 |
) |
|
1,387 |
|
|
(416 |
) |
Depreciation and amortization |
|
|
2,962 |
|
|
4,917 |
|
|
10,494 |
|
|
16,774 |
|
EBITDA |
|
|
(59,247 |
) |
|
54,844 |
|
|
16,397 |
|
|
(334,521 |
) |
Goodwill, intangible and other long-lived asset impairment |
|
|
106,841 |
|
|
2,108 |
|
|
107,222 |
|
|
472,192 |
|
Non-cash share-based compensation |
|
|
5,116 |
|
|
3,512 |
|
|
10,144 |
|
|
14,108 |
|
Interest rate derivatives (1) |
|
|
(14,120 |
) |
|
(45,038 |
) |
|
(26,865 |
) |
|
(86,066 |
) |
Acquisition-related costs (2) |
|
|
428 |
|
|
- |
|
|
465 |
|
|
69 |
|
Integration costs (3) |
|
|
497 |
|
|
3,266 |
|
|
1,732 |
|
|
16,493 |
|
Legal costs and settlements associated with acquisition matters (4) |
|
|
346 |
|
|
876 |
|
|
(4,796 |
) |
|
3,385 |
|
COVID-related costs, net of reimbursement (5) |
|
|
- |
|
|
- |
|
|
- |
|
|
5,087 |
|
Restructuring (6) |
|
|
985 |
|
|
2,149 |
|
|
5,733 |
|
|
2,149 |
|
Other legal matters (7) |
|
|
- |
|
|
- |
|
|
(5,000 |
) |
|
- |
|
Other system transition costs, professional fees and other (8) |
|
|
(4,655 |
) |
|
3,030 |
|
|
(4,505 |
) |
|
6,768 |
|
Total adjustments |
|
$ |
95,438 |
|
$ |
(30,097 |
) |
$ |
84,130 |
|
$ |
434,185 |
|
Adjusted EBITDA |
|
$ |
36,191 |
|
$ |
24,747 |
|
$ |
100,527 |
|
$ |
99,664 |
|
The following table reconciles net (loss) income to adjusted net (loss) income and presents adjusted net (loss) income per diluted share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three-month periods ended |
|
For the nine-month periods ended |
|
(dollars in thousands, except share and per share data) |
September 30, 2023 |
|
October 1, 2022 |
|
September 30, 2023 |
|
October 1, 2022 |
|
Net (loss) income |
$ |
(102,389 |
) |
$ |
24,298 |
|
$ |
(108,788 |
) |
$ |
(424,255 |
) |
Income tax expense (benefit) |
|
631 |
|
|
(2,669 |
) |
|
1,387 |
|
|
(416 |
) |
Goodwill, intangible and other long-lived asset impairment |
|
106,841 |
|
|
2,108 |
|
|
107,222 |
|
|
472,192 |
|
Non-cash share-based compensation |
|
5,116 |
|
|
3,512 |
|
|
10,144 |
|
|
14,108 |
|
Interest rate derivatives (1) |
|
(14,120 |
) |
|
(45,038 |
) |
|
(26,865 |
) |
|
(86,066 |
) |
Acquisition-related costs (2) |
|
428 |
|
|
- |
|
|
465 |
|
|
69 |
|
Integration costs (3) |
|
497 |
|
|
3,266 |
|
|
1,732 |
|
|
16,493 |
|
Legal costs and settlements associated with acquisition matters (4) |
|
346 |
|
|
876 |
|
|
(4,796 |
) |
|
3,385 |
|
COVID-related costs, net of reimbursement (5) |
|
- |
|
|
- |
|
|
- |
|
|
5,087 |
|
Restructuring (6) |
|
985 |
|
|
2,149 |
|
|
5,733 |
|
|
2,149 |
|
Other legal matters (7) |
|
- |
|
|
- |
|
|
(5,000 |
) |
|
- |
|
Other system transition costs, professional fees and other (8) |
|
(4,655 |
) |
|
3,030 |
|
|
(4,505 |
) |
|
6,768 |
|
Total adjustments |
|
96,069 |
|
|
(32,766 |
) |
|
85,517 |
|
|
433,769 |
|
Adjusted pre-tax net (loss) income |
|
(6,320 |
) |
|
(8,468 |
) |
|
(23,271 |
) |
|
9,514 |
|
Income tax benefit (expense) on adjusted pre-tax (loss) income (9) |
|
1,580 |
|
|
2,117 |
|
|
5,818 |
|
|
(2,379 |
) |
Adjusted net (loss) income |
$ |
(4,740 |
) |
$ |
(6,351 |
) |
$ |
(17,453 |
) |
$ |
7,135 |
|
Weighted average shares outstanding, diluted |
|
189,139 |
|
|
186,166 |
|
|
189,632 |
|
|
185,327 |
|
Adjusted net (loss) income per diluted share (10) |
$ |
(0.03 |
) |
$ |
(0.03 |
) |
$ |
(0.09 |
) |
$ |
0.04 |
|
The following footnotes are applicable to tables above that reconcile (i) net (loss) income to EBITDA and Adjusted EBITDA and (ii) net (loss) income to adjusted net (loss) income.
10
1)Represents valuation adjustments and settlements associated with interest rate derivatives that are not included in interest expense, net. Such items are included in other income.
2)Represents transaction costs incurred in connection with planned, completed, or terminated acquisitions, which include investment banking fees, legal diligence and related documentation costs, and finance and accounting diligence and documentation, as presented on the Company’s consolidated statements of operations.
3)Represents (i) costs associated with our Integration Management Office, which focuses on our integration efforts and transformational projects such as systems conversions and implementations, material cost reduction and restructuring projects, among other things, of $0.3 million and $1.1 million for the three and nine-month periods ended September 30, 2023, respectively, and $0.6 million and $2.3 million for the three and nine-month periods ended October 1, 2022, respectively; and (ii) transitionary costs incurred to integrate acquired companies into our field and corporate operations of $0.2 million and $0.6 million for the three and nine-month periods ended September 30, 2023, respectively, and $2.7 million and $14.2 million for the three and nine-month periods ended October 1, 2022, respectively. Transitionary costs incurred to integrate acquired companies include IT consulting costs and related integration support costs; salary, severance and retention costs associated with duplicative acquired company personnel until such personnel are exited from the Company; accounting, legal and consulting costs; expenses and impairments related to the closure and consolidation of overlapping markets of acquired companies, including lease termination and relocation costs; costs associated with terminating legacy acquired company contracts and systems; and one-time costs associated with rebranding our acquired companies and locations to the Aveanna brand.
4)Represents legal and forensic costs, as well as settlements associated with resolving legal matters arising during or as a result of our acquisition-related activities. This primarily includes (i) costs of $0.0 million and $0.3 million for the three and nine-month periods ended September 30, 2023, respectively, and $0.8 million and $3.1 million for the three and nine-month periods ended October 1, 2022, respectively, to comply with the U.S. Department of Justice, Antitrust Division’s grand jury subpoena related to nurse wages and hiring activities in certain of our markets, in connection with a terminated transaction, and (ii) release of reserve of $3.6 million for the nine-month periods ended September 30, 2023, related to the settlement of a legal matter resulting from a 2020 acquisition.
5)Represents costs incurred as a result of the COVID-19 environment, primarily including, but not limited to, (i) relief, vaccine, and hero pay provided to our caregivers; staffing and retention related incentives to attract and retain caregivers in the midst of the Omicron surge; and other incremental compensation costs; (ii) sick leave for our caregivers required by OSHA's Emergency Temporary Standard, costs required to comply with federal, state and local vaccination mandates and testing requirements, and worker compensation costs for mandated quarantine time; (iii) incremental PPE costs; and (iv) salary, severance and lease termination costs associated with workforce reductions necessitated by COVID-19; net of temporary reimbursement rate increases provided by certain state Medicaid and Medicaid Managed Care programs.
6)Represents costs associated with restructuring our branch and regional administrative footprint as well as our corporate overhead infrastructure costs for the three and nine-month periods ended September 30, 2023, in order to appropriately size our resources to current volumes, including: (i) branch and regional salary and severance costs; (ii) corporate salary and severance costs; and (iii) rent and lease termination costs associated with the closure of certain office locations.
7)Represents adjustments to an accrued legal settlement and the related costs and expenses associated with a certain judgment rendered against the Company related to a civil litigation matter in Texas.
8)Represents (i) costs associated with the implementation of, and transition to, new electronic medical record systems, billing and collection systems, duplicative system costs while such transformational projects are in-process, and other system transition costs of $0.6 million and $1.3 million for the three and nine-month period ended September 30, 2023, respectively, and $2.2 million and $5.4 million for the three and nine-month periods ended October 1, 2022, respectively, there were no such costs incurred in the three-month period ended July 1, 2023, (ii) a $5.1 million non-cash gain on the acquisition of certain business licenses and other net assets in the three and nine-month periods ended September 30, 2023, there were no such gains recorded in any other periods, and (iii) other costs or (income) that are either non-cash or non-core to the Company’s ongoing operations of $(0.2) million and $(0.8) million for the three and nine-month periods ended September 30, 2023, respectively, and $0.8 million and $1.4 million for the three and nine-month periods ended October 1, 2022, respectively.
9)Derived utilizing a combined statutory rate of 25% for the three and nine-month periods ended September 30, 2023, and October 1, 2022, respectively, and applied to the respective adjusted pre-tax (loss) income.
10)Adjustments used to reconcile net (loss) income per diluted share on a GAAP basis to adjusted net (loss) income per diluted share are comprised of the same adjustments, inclusive of the tax impact, used to reconcile net (loss) income to adjusted net (loss) income divided by the weighted-average diluted shares outstanding during the period.
The table below reflects the increase or decrease, and aggregate impact, to the line items included on our consolidated statements of operations based upon the adjustments used in arriving at Adjusted EBITDA from EBITDA for the periods indicated.
11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three-month periods ended |
|
For the nine-month periods ended |
|
(dollars in thousands) |
September 30, 2023 |
|
October 1, 2022 |
|
September 30, 2023 |
|
October 1, 2022 |
|
Revenue |
$ |
- |
|
$ |
- |
|
$ |
- |
|
$ |
- |
|
Cost of revenue, excluding depreciation and amortization |
|
166 |
|
|
675 |
|
|
(4,512 |
) |
|
5,850 |
|
Branch and regional administrative expenses |
|
2,765 |
|
|
3,947 |
|
|
6,129 |
|
|
7,512 |
|
Corporate expenses |
|
4,445 |
|
|
8,299 |
|
|
10,629 |
|
|
35,117 |
|
Goodwill impairment |
|
105,136 |
|
|
- |
|
|
105,136 |
|
|
470,207 |
|
Acquisition-related costs |
|
428 |
|
|
- |
|
|
465 |
|
|
69 |
|
Other operating (income) expense |
|
(5,090 |
) |
|
2,121 |
|
|
(8,735 |
) |
|
1,952 |
|
Other income |
|
(12,412 |
) |
|
(45,139 |
) |
|
(24,982 |
) |
|
(86,522 |
) |
Total adjustments |
$ |
95,438 |
|
$ |
(30,097 |
) |
$ |
84,130 |
|
$ |
434,185 |
|
The following table reconciles the net increase (decrease) in cash and cash equivalents to free cash flow:
|
|
|
|
|
|
|
For the nine-month period ended |
|
(dollars in thousands) |
|
September 30, 2023 |
|
Net cash provided by operations |
|
|
25,677 |
|
Purchases of property and equipment, and software |
|
|
(4,548 |
) |
Principal payments of term loans |
|
|
(6,900 |
) |
Principal payments of notes payable and financing lease obligations |
|
|
(7,814 |
) |
Settlements with swap counterparties |
|
|
10,442 |
|
Free cash flow |
|
$ |
16,857 |
|
12
v3.23.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Aveanna Healthcare (NASDAQ:AVAH)
Historical Stock Chart
From Apr 2024 to May 2024
Aveanna Healthcare (NASDAQ:AVAH)
Historical Stock Chart
From May 2023 to May 2024
